JSR Acquires Crown Biosciences

JSR Corporation has agreed to purchase Crown Bioscience International at 12 Billion New Taiwan Dollar. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include contract research and development capabilities.

Upon completion of the acquisition, JSR Life Sciences’ will have a full suite of integrated capabilities that extend from pure research, to drug discovery, diagnostics development, cell line development and process development, through to GMP manufacturing.

“We are positioning to be the clear choice for innovation-driven strategic partnerships,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “CrownBio, and its science-rich approach, is an ideal fit to support that goal. We’re bringing together innovative competencies that will lead to better solutions for pharma and improve their ability to take therapeutics to the market.”

Translational platforms, bioinformatics and modeling capabilities, like CrownBio’s patient-derived xenograft (PDX) models, are becoming fundamentally important to the development and commercialization of diagnostics and therapeutics. JSR’s forecast, based on consultation with CrownBio’s management team, is for the company to realize Revenue and EBITDA margin of 90 and 20 M USD respectively in 2018, with the understanding that such projected financial information may vary from actual results.

  • <<
  • >>